JY
ADCT icon

Jeff Yass’s ADC Therapeutics ADCT Stock Holding History

Jeff Yass’s Portfolio ADCT Stock Details ADCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-76,268
Closed -$286K – 13296
2026
Q1 		$286K Buy
76,268
+56,090
+278% +$221K ﹤0.01% 10965
2025
Q4 		$71.2K Buy
+20,178
New +$81.9K ﹤0.01% 11620
2025
Q3 		– Sell
-115,232
Closed -$363K – 12247
2025
Q2 		$309K Buy
115,232
+11,452
+11% +$24.1K ﹤0.01% 10275
2025
Q1 		$146K Buy
103,780
+52,582
+103% +$89.3K ﹤0.01% 11253
2024
Q4 		$102K Buy
+51,198
New +$134K ﹤0.01% 11330
2024
Q3 		– Sell
-54,126
Closed -$171K – 11860
2024
Q2 		$171K Buy
+54,126
New +$215K ﹤0.01% 10555
2024
Q1 		– Sell
-20,689
Closed -$76.3K – 12056
2023
Q4 		$34.3K Buy
+20,689
New +$19.1K ﹤0.01% 11844
2023
Q3 		– Sell
-18,788
Closed -$40.4K – 11922
2023
Q2 		$40.4K Sell
18,788
-7,240
-28% -$16.3K ﹤0.01% 11415
2023
Q1 		$50.8K Buy
26,028
+12,065
+86% +$44.5K ﹤0.01% 11698
2022
Q4 		$53.6K Sell
13,963
-3,959
-22% -$15.8K ﹤0.01% 11353
2022
Q3 		$86K Buy
+17,922
New +$130K ﹤0.01% 11814
2022
Q1 		– Sell
-25,866
Closed -$411K – 12882
2021
Q4 		$522K Buy
+25,866
New +$624K ﹤0.01% 9075
2021
Q3 		– Sell
-32,124
Closed -$823K – 12654
2021
Q2 		$782K Sell
32,124
-67,164
-68% -$1.56M ﹤0.01% 8437
2021
Q1 		$2.42M Buy
99,288
+90,694
+1,055% +$2.63M ﹤0.01% 5443
2020
Q4 		$275K Buy
+8,594
New +$282K ﹤0.01% 9433

Other funds holding ADCT

NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Jeff Yass's ADCT Position: Q2 2026 in Review

Jeff Yass sold out of ADC Therapeutics (ADCT) in Q2 2026, closing a stake of 76,268 shares — an estimated $286K sold.

Jeff Yass first reported a position in ADCT in Q4 2020 and held it in 15 quarters. The position peaked at $2.42M in Q1 2021. 113 funds tracked by Wall St. Rank hold ADCT as of Q2 2026.

  • Jeff Yass reported no remaining ADC Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Jeff Yass sold 76,268 ADC Therapeutics shares in Q2 2026, an estimated $286K.
  • Jeff Yass first reported a position in ADC Therapeutics in Q4 2020 and held it in 15 quarters.
  • Jeff Yass's ADC Therapeutics position peaked at $2.42M in Q1 2021.
  • 113 funds tracked by Wall St. Rank held ADC Therapeutics as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.